Autor/es reacciones

Marcos López Hoyos

Scientific Director of the Valdecilla Health Research Institute (IDIVAL) and Professor of Immunology at the University of Cantabria

The approval of Hipra's vaccine is excellent news. Firstly, we have a vaccine that will work with a single dose and induce a broader and longer-lasting immune response than previously available vaccines. In addition, this vaccine can be kept refrigerated and does not need to be frozen. Finally, and especially relevant, it means that we now have a Spanish company capable of manufacturing human vaccines for this and other infections in the future.

EN